RecruitingPhase 1NCT05753059

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2


Sponsor

Yale University

Enrollment

50 participants

Start Date

Aug 10, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating why some heart failure patients stop responding to water pills (diuretics) — a condition called diuretic resistance — by carefully measuring how their kidneys and body handle fluids. Understanding this could lead to better treatments for fluid buildup in heart failure. **You may be eligible if...** - You have been diagnosed with heart failure - Your heart failure medications are stable with no planned changes during the study - You have not had an unplanned hospital stay in the last 2 weeks - Your fluid levels are currently well-controlled - Your potassium blood level is within normal range **You may NOT be eligible if...** - Your heart failure treatment plan is being adjusted - You recently had an emergency hospitalization - You have unstable fluid levels or abnormal potassium Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21

DRUGAmiloride

This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21

DRUGBendroflumethiazide

This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21


Locations(1)

Yale University

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05753059


Related Trials